NCT05864248
Feasibility Study SA of the Supira System for HRPCI
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Apr 30, 2025 to Feb 6, 2026 Show 4 more changesShow less
- Eligibility criteria shortened, about 12 words
- Trial completed
- Study completion date changed from estimate of Mar 30, 2026 to Feb 6, 2026
- Site details revised at 1 of 2 sites
Minor Trial status: Recruiting to Active, Not Recruitingv4 Show 4 more changesShow less
- Enrollment target: estimated 115 to confirmed 71
- Primary completion date changed from estimate of Sep 30, 2025 to Apr 30, 2025
- Study completion date: Sep 30, 2025 to Mar 30, 2026
- Site details revised at 2 of 2 sites
- Notable Primary endpoints revised (2)
- Secondary endpoints revised (5)
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
- Enrollment target: 40 to 115
- Primary and study completion dates pushed to Sep 30, 2025
- Start date changed from estimate of Jun 1, 2023 to Sep 13, 2023
- Eligibility criteria expanded, about 275 words
- Primary endpoints revised (2)
- Study sites: 0 to 2
- Secondary endpoints: 4 to 5
- Study description expanded, about 10 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Primary Feasibility Endpoint: Successful initiation and maintenance of hemodynamic support without sustained hypotension throughout the index procedure.
Timeframe: From device delivery through device removal (up to 4 hours).
Primary Safety Endpoint: Rate of composite major device-related adverse events (MDRAEs), from device delivery through device removal.
Timeframe: From device delivery through device removal (up to 4 hours).
Secondary (5)
Rate of Technical Success.
Rate of Procedural Success
Rate of composite MDRAEs from device removal through hospital discharge or 72 hours post-procedure, whichever comes first.
Rate of composite MDRAE from hospital discharge or 72 hours post-procedure (whichever occurs first) through 30 days post device removal.
Rate of composite MDRAE from 30 days to 90 days post device removal (for subjects enrolled and treated after the first 30 subjects).
Arms and interventions
HRPCI patientsExperimental
Patients undergoing non-emergent, high-risk percutaneous coronary interventions.
Devices: Supira System
Sites
2 sites in 1 country